FOLFIRINOX
FOLFIRINOX is a combination chemotherapy regimen used in the treatment of pancreatic cancer. It is considered one of the most effective treatments for metastatic pancreatic cancer, offering a survival benefit over other chemotherapy regimens. FOLFIRINOX is an acronym that stands for the four drugs included in the regimen: Folinic acid (leucovorin), Fluorouracil (5-FU), Irinotecan, and Oxaliplatin.
Components of FOLFIRINOX[edit]
- Folinic acid (Leucovorin): A form of folic acid that enhances the effectiveness of Fluorouracil.
- Fluorouracil (5-FU): An antimetabolite that interferes with the synthesis of DNA and RNA.
- Irinotecan: A topoisomerase inhibitor that prevents DNA from unwinding, which is necessary for DNA replication.
- Oxaliplatin: A platinum-based drug that causes DNA crosslinking and inhibits DNA synthesis.
Mechanism of Action[edit]
FOLFIRINOX works by combining the mechanisms of its four components to target and kill rapidly dividing cancer cells. Folinic acid enhances the binding of Fluorouracil to the enzyme thymidylate synthase, increasing its cytotoxic effects. Fluorouracil inhibits thymidylate synthase, leading to a decrease in thymidine production, which is essential for DNA synthesis. Irinotecan inhibits topoisomerase I, preventing DNA replication and transcription. Oxaliplatin forms DNA adducts that disrupt DNA synthesis and transcription.
Indications[edit]
FOLFIRINOX is primarily indicated for the treatment of metastatic pancreatic cancer. It is also used in some cases of locally advanced pancreatic cancer and has been studied for use in other types of gastrointestinal cancers.
Side Effects[edit]
The regimen is associated with significant side effects, which can include:
Administration[edit]
FOLFIRINOX is administered intravenously, typically in a hospital or clinical setting. The treatment cycle usually lasts for two weeks, with the drugs given on specific days within the cycle.
Efficacy[edit]
Clinical trials have shown that FOLFIRINOX can significantly improve overall survival and progression-free survival in patients with metastatic pancreatic cancer compared to other chemotherapy regimens such as gemcitabine.
Related Pages[edit]
Categories[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
